Bank of New York Mellon Corp purchased a new stake in shares of Recro Pharma, Inc. (NASDAQ:REPH) during the first quarter, Holdings Channel reports. The fund purchased 17,877 shares of the specialty pharmaceutical company’s stock, valued at approximately $156,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Wells Fargo & Company MN boosted its position in Recro Pharma by 3.0% in the first quarter. Wells Fargo & Company MN now owns 17,200 shares of the specialty pharmaceutical company’s stock valued at $150,000 after buying an additional 500 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in Recro Pharma by 17.8% in the first quarter. Janney Montgomery Scott LLC now owns 12,485 shares of the specialty pharmaceutical company’s stock valued at $109,000 after buying an additional 1,885 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in Recro Pharma during the first quarter valued at about $150,000. Institutional investors and hedge funds own 64.15% of the company’s stock.

Recro Pharma, Inc. (NASDAQ REPH) traded down 0.68% during trading on Friday, reaching $7.25. The company’s stock had a trading volume of 1,257 shares. The stock’s market cap is $138.11 million. The firm has a 50 day moving average price of $7.37 and a 200-day moving average price of $7.64. Recro Pharma, Inc. has a 52-week low of $5.81 and a 52-week high of $10.85.

Recro Pharma (NASDAQ:REPH) last announced its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.06. The company had revenue of $16.93 million for the quarter, compared to the consensus estimate of $14.90 million. Recro Pharma had a negative return on equity of 61.09% and a negative net margin of 45.15%. On average, analysts expect that Recro Pharma, Inc. will post ($2.35) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/11/bank-of-new-york-mellon-corp-purchases-shares-of-17877-recro-pharma-inc-nasdaqreph.html.

Several research firms recently issued reports on REPH. Roth Capital set a $20.00 price target on Recro Pharma and gave the company a “buy” rating in a report on Saturday, May 13th. Piper Jaffray Companies set a $11.00 price target on Recro Pharma and gave the company a “buy” rating in a report on Tuesday, July 25th. Zacks Investment Research cut Recro Pharma from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. Finally, Janney Montgomery Scott cut Recro Pharma from a “buy” rating to a “fair value” rating and decreased their price target for the company from $21.00 to $6.50 in a report on Wednesday, June 14th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Recro Pharma has an average rating of “Buy” and a consensus price target of $14.00.

In related news, major shareholder James E. Flynn sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $6.74, for a total transaction of $67,400.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider James E. Flynn sold 110,447 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $6.39, for a total value of $705,756.33. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 215,762 shares of company stock worth $1,430,830. 21.60% of the stock is owned by company insiders.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Want to see what other hedge funds are holding REPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recro Pharma, Inc. (NASDAQ:REPH).

Institutional Ownership by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.